

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYS6077 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the SYS6077 injection (the “**Product**”) developed by the Group has obtained the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. The indication for this approved clinical trial is advanced malignant tumours.

The Product is a universal, off-the-shelf therapeutic messenger RNA (“**mRNA**”) cancer vaccine developed based on the Group’s nano-delivery technology platform. By encoding multiple tumour neoantigens, it induces antigen-specific T-cell immune responses, thereby enhancing the body’s ability to recognise and attack tumour cells. Preclinical studies demonstrated that the Product induced antigen-specific T-cell immune responses against multiple tumour antigens, and exhibited anti-tumour activity in multiple preclinical tumour models. Based on the aforementioned research results, the Group will initiate clinical studies of the Product to further evaluate its safety, immunogenicity, and preliminary anti-tumour activity in patients with malignant tumours.

The approval of the clinical trial for the Product marks a significant step forward for the Group in mRNA technology and tumour immunity, and it is expected to provide a novel treatment option for patients with malignant tumours in the future.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 28 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.